30 / 53
Crizotinib en SNC: DCR and ORR
56
63
18
53
62
65
33
46
71
55
Intracranial
Systemic
Intracranial (target
lesion BM)
Systemic
a
DCR at 12 weeks
ORR
NA
NA
NA, not applicable
a
n=22 for untreated BMs; n=18 for treated BMs
●
There was a positive and statistically significant correlation between systemic DCR at 12 weeks
and intracranial DCR at 12 weeks in patients with BMs (correlation coefficient, 0.7652; P<0.001)
Previously untreated for BMs (n=109
)
Previously treated for BMs (n=166)
No BMs detected (n=613)
0
10
20
30
40
50
60
70
80
Percent of patients (95% CI)
Costa DB, et al. J Clin Oncol 2015;33,181